1605317-40-5Relevant articles and documents
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmor
Johnson, Christopher N.,Ahn, Jong Sook,Buck, Ildiko M.,Chiarparin, Elisabetta,Day, James E. H.,Hopkins, Anna,Howard, Steven,Lewis, Edward J.,Martins, Vanessa,Millemaggi, Alessia,Munck, Joanne M.,Page, Lee W.,Peakman, Torren,Reader, Michael,Rich, Sharna J.,Saxty, Gordon,Smyth, Tomoko,Thompson, Neil T.,Ward, George A.,Williams, Pamela A.,Wilsher, Nicola E.,Chessari, Gianni
supporting information, p. 7314 - 7329 (2018/09/06)
Inhibitor of apoptosis proteins (IAPs) are promising anticancer targets, given their roles in the evasion of apoptosis. Several peptidomimetic IAP antagonists, with inherent selectivity for cellular IAP (cIAP) over X-linked IAP (XIAP), have been tested in